publication . Article . 2021

COVID-19 in Autoinflammatory Diseases with Immunosuppressive Treatment

Tatjana Welzel; Samuel Dembi Samba; Reinhild Klein; Johannes N. van den Anker; Jasmin B Kuemmerle-Deschner;
Open Access English
  • Published: 01 Feb 2021 Journal: Journal of Clinical Medicine (issn: 2077-0383, Copyright policy)
  • Publisher: Multidisciplinary Digital Publishing Institute
COVID-19 disease increases interleukin (IL)-1β release. Anti-IL-1-treatment is effective in IL-1-mediated autoinflammatory diseases (AID). This case series presents COVID-19 in patients with IL-1-mediated and unclassified AID with immunosuppressive therapy (IT). Patient 1 is a 34-year-old woman with an unclassified AID and methotrexate. Patients 2 and 3 (14-year-old girl and 12-year-old boy, respectively) have a Cryopyrin-Associated Periodic Syndrome (NLRP3 p.Q703K heterozygous, CAPS) treated with canakinumab 150 mg/month since three and five years, respectively. Patient 4 is a 15-year-old girl who has had familial Mediterranean fever (MEFV p.M694V homozygous) for 3 years treated with canakinumab 150 mg/month and colchicine. All patients had a mild acute COVID-19 course, particularly the adolescent patients. A few weeks after COVID-19 recovery, both CAPS patients developed increased AID activity, necessitating anti-IL-1-treatment intensification in one patient. At day 100, one out of four patients (25%) showed positive antibody response to SARS-CoV-2. This is one of the first reports providing follow-up data about COVID-19 in AID. The risk for severe acute COVID-19 disease was mild/moderate, but increased AID activity post-COVID-19 was detected. Follow-up data and data combination are needed to expand understanding of COVID-19 and SARS-CoV-2 immunity in AID and the role of IT.
Persistent Identifiers
Fields of Science and Technology classification (FOS)
03 medical and health sciences, 0302 clinical medicine, 030203 arthritis & rheumatology, 030212 general & internal medicine
Sustainable Development Goals (SDG)
3. Good health
free text keywords: Interleukin-1, autoinflammatory diseases, CAPS, FMF, coronavirus, SARS-CoV-2 antibody response, Article, General Medicine, Internal medicine, medicine.medical_specialty, medicine, business.industry, business, Disease, Interleukin, Colchicine, chemistry.chemical_compound, chemistry, MEFV, Familial Mediterranean fever, medicine.disease, Canakinumab, medicine.drug, Immunity, Methotrexate, lcsh:Medicine, lcsh:R
Related Organizations
Any information missing or wrong?Report an Issue